|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E-mail contact: peled{at}hadassah.org.il
Hormone refractory metastatic prostate cancer remains an incurable disease. We found that high expression levels of the chemokine receptor CXCR4 correlated with the presence of metastatic disease in prostate cancer patients. Positive staining for CXCL12, the ligand for CXCR4, was mainly present in the tumor-associated blood vessels and basal cell hyperplasia. Subcutaneous xenografts of PC3 and 22Rv1 prostate tumors that overexpressed CXCR4 in NOD/SCID mice were two- to threefold larger in volume and weight vs. controls. Moreover, blood vessel density, functionality, invasiveness of tumors into the surrounding tissues, and metastasis to the lymph node and lung were significantly increased in these tumors. Neutralizing the interactions of CXCL12/CXCR4 in vivo with CXCR4 specific antibodies inhibited the CXCR4-dependent tumor growth and vascularization. In vitro, CXCL12 induced the proliferation and VEGF secretion but not migration of PC3 and 22Rv1 cells overexpressing CXCR4. Similar effects of CXCR4 overexpression on tumor growth in vivo were also noted in two breast cancer lines, suggesting that the observed effect of CXCR4 is not unique to prostate tumor cells. Thus high levels of the chemokine receptor CXCR4 induce a more aggressive phenotype in prostate cancer cells and identify CXCR4 as a potential therapeutic target in advanced cases of metastatic prostate cancer.
Key words: chemokine receptor • prostate tumors
This article has been cited by other articles:
![]() |
S. Hassan, C. Ferrario, U. Saragovi, L. Quenneville, L. Gaboury, A. Baccarelli, O. Salvucci, and M. Basik The Influence of Tumor-Host Interactions in the Stromal Cell-Derived Factor-1/CXCR4 Ligand/Receptor Axis in Determining Metastatic Risk in Breast Cancer Am. J. Pathol., July 1, 2009; 175(1): 66 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Izhak, G. Wildbaum, Y. Zohar, R. Anunu, L. Klapper, A. Elkeles, J. Seagal, E. Yefenof, M. Ayalon-Soffer, and N. Karin A Novel Recombinant Fusion Protein Encoding a 20-Amino Acid Residue of the Third Extracellular (E3) Domain of CCR2 Neutralizes the Biological Activity of CCL2 J. Immunol., July 1, 2009; 183(1): 732 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. L. Muehlberg, Y.-H. Song, A. Krohn, S. P. Pinilla, L. H. Droll, X. Leng, M. Seidensticker, J. Ricke, A. M. Altman, E. Devarajan, et al. Tissue-resident stem cells promote breast cancer growth and metastasis Carcinogenesis, April 1, 2009; 30(4): 589 - 597. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Alexandre, R. A. Volpini, M. H. Shimizu, T. R. Sanches, P. Semedo, V. L. di Jura, N. O. Camara, A. C. Seguro, and L. Andrade Lineage-Negative Bone Marrow Cells Protect Against Chronic Renal Failure Stem Cells, March 1, 2009; 27(3): 682 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, Y. Lu, J. Wang, A. E. Koch, J. Zhang, and R. S. Taichman CXCR6 Induces Prostate Cancer Progression by the AKT/Mammalian Target of Rapamycin Signaling Pathway Cancer Res., December 15, 2008; 68(24): 10367 - 10377. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S Wicha, S. Liu, and G. Dontu Cancer Stem Cells: An Old Idea--A Paradigm Shift Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 383 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hatziapostolou, C. Polytarchou, D. Panutsopulos, L. Covic, and P. N. Tsichlis Proteinase-Activated Receptor-1-Triggered Activation of Tumor Progression Locus-2 Promotes Actin Cytoskeleton Reorganization and Cell Migration Cancer Res., March 15, 2008; 68(6): 1851 - 1861. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. F. Amersi, A. M. Terando, Y. Goto, R. A. Scolyer, J. F. Thompson, A. N. Tran, M. B. Faries, D. L. Morton, and D. S.B. Hoon Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine Clin. Cancer Res., February 1, 2008; 14(3): 638 - 645. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yang, L. K. Pham, C.-P. Liao, B. Frenkel, A. H. Reddi, and P. Roy-Burman A Novel Bone Morphogenetic Protein Signaling in Heterotypic Cell Interactions in Prostate Cancer Cancer Res., January 1, 2008; 68(1): 198 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hirata, Y. Hinoda, N. Kikuno, K. Kawamoto, A. V. Dahiya, Y. Suehiro, Y. Tanaka, and R. Dahiya CXCL12 G801A Polymorphism Is a Risk Factor for Sporadic Prostate Cancer Susceptibility Clin. Cancer Res., September 1, 2007; 13(17): 5056 - 5062. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-S. Chen, M.-Y. Wang, S.-N. Wu, J.-L. Su, C.-C. Hong, S.-E. Chuang, M.-W. Chen, K.-T. Hua, Y.-L. Wu, S.-T. Cha, et al. CTGF enhances the motility of breast cancer cells via an integrin-{alpha}vbeta3-ERK1/2-dependent S100A4-upregulated pathway J. Cell Sci., June 15, 2007; 120(12): 2053 - 2065. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Qiao, J. D. Iglehart, and A. B. Pardee Metastatic Potential of 21T Human Breast Cancer Cells Depends on Akt/Protein Kinase B Activation Cancer Res., June 1, 2007; 67(11): 5293 - 5299. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Miki, B. Furusato, H. Li, Y. Gu, H. Takahashi, S. Egawa, I. A. Sesterhenn, D. G. McLeod, S. Srivastava, and J. S. Rhim Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT-Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens Cancer Res., April 1, 2007; 67(7): 3153 - 3161. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tsoli, P. K Tsantoulis, A. Papalambros, B. Perunovic, D. England, D. A Rawlands, G. M Reynolds, D. Vlachodimitropoulos, S. L Morgan, C. A Spiliopoulou, et al. Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer J. Clin. Pathol., March 1, 2007; 60(3): 261 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kryczek, S. Wei, E. Keller, R. Liu, and W. Zou Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis Am J Physiol Cell Physiol, March 1, 2007; 292(3): C987 - C995. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Siddiqui, K. A. Harvey, G. P. Zaloga, and W. Stillwell Modulation of Lipid Rafts by {Omega}-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support Nutr Clin Pract, February 1, 2007; 22(1): 74 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kalinkovich, S. Tavor, A. Avigdor, J. Kahn, A. Brill, I. Petit, P. Goichberg, M. Tesio, N. Netzer, E. Naparstek, et al. Functional CXCR4-Expressing Microparticles and SDF-1 Correlate with Circulating Acute Myelogenous Leukemia Cells. Cancer Res., November 15, 2006; 66(22): 11013 - 11020. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Wald, U. Izhar, G. Amir, S. Avniel, Y. Bar-Shavit, H. Wald, I. D. Weiss, E. Galun, and A. Peled CD4+CXCR4highCD69+ T Cells Accumulate in Lung Adenocarcinoma J. Immunol., November 15, 2006; 177(10): 6983 - 6990. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ueda, N. F. Neel, E. Schutyser, D. Raman, and A. Richmond Deletion of the COOH-Terminal Domain of CXC Chemokine Receptor 4 Leads to the Down-regulation of Cell-to-Cell Contact, Enhanced Motility and Proliferation in Breast Carcinoma Cells Cancer Res., June 1, 2006; 66(11): 5665 - 5675. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Holland, M. Kochetkova, C. Akekawatchai, M. Dottore, A. Lopez, and S. R. McColl Differential functional activation of chemokine receptor CXCR4 is mediated by g proteins in breast cancer cells. Cancer Res., April 15, 2006; 66(8): 4117 - 4124. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Wicha, S. Liu, and G. Dontu Cancer Stem Cells: An Old Idea--A Paradigm Shift Cancer Res., February 15, 2006; 66(4): 1883 - 1890. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schabath, S. Runz, S. Joumaa, and P. Altevogt CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells J. Cell Sci., January 15, 2006; 119(2): 314 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Kaifi, E. F. Yekebas, P. Schurr, D. Obonyo, R. Wachowiak, P. Busch, A. Heinecke, K. Pantel, and J. R. Izbicki Tumor-Cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer J Natl Cancer Inst, December 21, 2005; 97(24): 1840 - 1847. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kukreja, A. B. Abdel-Mageed, D. Mondal, K. Liu, and K. C. Agrawal Up-regulation of CXCR4 Expression in PC-3 Cells by Stromal-Derived Factor-1{alpha} (CXCL12) Increases Endothelial Adhesion and Transendothelial Migration: Role of MEK/ERK Signaling Pathway-Dependent NF-{kappa}B Activation Cancer Res., November 1, 2005; 65(21): 9891 - 9898. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Miwa, A. Mizokami, E. T. Keller, R. Taichman, J. Zhang, and M. Namiki The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4-Induced Invasion in Prostate Cancer Cancer Res., October 1, 2005; 65(19): 8818 - 8825. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Dimitroff, L. Descheny, N. Trujillo, R. Kim, V. Nguyen, W. Huang, K. J. Pienta, J. L. Kutok, and M. A. Rubin Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells Cancer Res., July 1, 2005; 65(13): 5750 - 5760. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-B. Peng, V. Peek, Y. Zhai, D. C. Paul, Q. Lou, X. Xia, T. Eessalu, W. Kohn, and S. Tang Akt Activation, but not Extracellular Signal-Regulated Kinase Activation, Is Required for SDF-1{alpha}/CXCR4-Mediated Migration of Epitheloid Carcinoma Cells Mol. Cancer Res., April 1, 2005; 3(4): 227 - 236. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |